These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27654746)

  • 1. Recent advance in lipid management: Focus on PCSK9I (Proprotein Convertase Subtilisin/ Kexin 9 Inhibitors).
    Kalra S
    J Pak Med Assoc; 2016 Sep; 66(9):1191-1193. PubMed ID: 27654746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
    Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
    Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Preoperative Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor on Carotid Artery Stenting.
    Shingai Y; Kimura N; Doijiri R; Takahashi K; Yokosawa M; Kanoke A; Kikuchi T; Sugawara T; Tominaga T
    World Neurosurg; 2020 Mar; 135():e36-e42. PubMed ID: 31655235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
    Noel ZR; Beavers CJ
    Am J Med; 2017 Feb; 130(2):229.e1-229.e4. PubMed ID: 27751895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
    Giglio RV; Muzurović EM; Patti AM; Toth PP; Agarwal MA; Almahmeed W; Klisic A; Ciaccio M; Rizzo M
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231186855. PubMed ID: 37448204
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-world lipid lowering effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: A single-centre study.
    Han J; Bilgrami S; Ross S; Broadhead H; Attar N
    Int J Cardiol; 2021 Jan; 322():240-244. PubMed ID: 32827563
    [No Abstract]   [Full Text] [Related]  

  • 8. Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention.
    Ali A; Costanzo P; Hoye A
    Curr Pharm Des; 2018; 24(4):442-450. PubMed ID: 29332570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
    Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
    J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibition: A Lipocrinologic Review.
    Kalra S
    J Assoc Physicians India; 2018 Oct; 66(10):70-72. PubMed ID: 31317713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
    Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
    Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein Convertase Subtilisin Kexin 9 Inhibitors.
    Pirillo A; Catapano AL
    Cardiol Clin; 2018 May; 36(2):241-256. PubMed ID: 29609754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
    Stein EA
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):97-105. PubMed ID: 26859553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
    Hess GP; Natarajan P; Faridi KF; Fievitz A; Valsdottir L; Yeh RW
    Circulation; 2017 Dec; 136(23):2210-2219. PubMed ID: 29084735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-Lowering Therapy With Monoclonal Antibodies to Proprotein Convertase Subtilisin-Kexin Type 9　- Lessons From Recent Clinical Trials.
    Ishii H; Murohara T
    Circ J; 2017 Sep; 81(10):1386-1387. PubMed ID: 28579602
    [No Abstract]   [Full Text] [Related]  

  • 16. The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy.
    Smith L; Mosley J; Yates J; Caswell L
    J Pharm Pharm Sci; 2016; 19(1):137-46. PubMed ID: 27096698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of proprotein convertase subtilisin/kexin type-9 inhibition in secondary prevention: from clinical trials to real-world experience.
    Pandey AS; Bajaj HS; Garg V; Pandey A; Verma S
    Curr Opin Cardiol; 2017 Sep; 32(5):633-641. PubMed ID: 28557865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years.
    de Carvalho LSF; Campos AM; Sposito AC
    Diabetes Care; 2018 Feb; 41(2):364-367. PubMed ID: 29180351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Treatment for Repeated In-stent Restenosis in a Coronary Artery.
    Akiyama T; Ozaki K; Takano T; Yoneyama S; Kubota N; Okubo T; Ikegami R; Hoyano M; Yanagawa T; Inomata T
    Intern Med; 2023 Nov; 62(22):3361-3365. PubMed ID: 37005262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.
    Rane PB; Patel J; Harrison DJ; Shepherd J; Leith A; Bailey H; Piercy J
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):103-108. PubMed ID: 28849360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.